Oncotarget

Corrections:

Correction: Prorenin receptor acts as a potential molecular target for pancreatic ductal adenocarcinoma diagnosis

PDF

Oncotarget. 2019; 10:558-558. https://doi.org/10.18632/oncotarget.26597

Metrics: PDF 280 views  |   ?  

Bin Zhao1 and Hong Zhao1,2

1 Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan
2 Institute of Biomedical Engineering & Nanomedicine, National Health Research Institutes, Miaoli, Taiwan
3 Department of General Surgery, Taipei Veterans General Hospital, and National Yang Ming University, Taipei, Taiwan
4 Institute of Molecular Medicine and Bioengineering, National Chiao Tung University, Hsinchu, Taiwan
* These authors have contributed equally to this work

Published: January 11, 2019

This article has been corrected: Due to an error in proofreading, the total ERK, AKT, and S6K in Figure 4A are incorrect. The proper Figure 4A is shown below. In addition, updates have been made to the 3rd affiliation and a 4th affiliation has been added. Both are shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

3 Department of General Surgery, Taipei Veterans General Hospital, and National Yang Ming University, Taipei, Taiwan
4 Institute of Molecular Medicine and Bioengineering, National Chiao Tung University, Hsinchu, Taiwan

Original article: Oncotarget. 2016; 7:55437-55448. DOI: https://doi.org/10.18632/oncotarget.10583.

Figure 4: Role of PRR in MAPK and PI3K/Akt pathways. Western results have shown in A. overexpression of human PRR in Panc-1 cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26597